Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
CTAD 2022 and Ctad 2022
View overview page
5:24
Lecanemab: a review
Alvaro Pascual-Leone
• 9 Jan 2023
3:02
Lecanemab: drawbacks to consider
Alvaro Pascual-Leone
• 9 Jan 2023
1:35
Lecanemab vs aducanumab
Alvaro Pascual-Leone
• 9 Jan 2023
2:10
FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?
Alvaro Pascual-Leone
• 9 Jan 2023
4:30
Primary care digital screening tool for Alzheimer’s disease
Alvaro Pascual-Leone
• 9 Jan 2023
2:07
Remaining challenges in bringing fluid biomarkers into clinical practice
Henrik Schinke
• 15 Dec 2022
5:21
Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis
Henrik Schinke
• 15 Dec 2022
1:49
Bringing the pTau/Aβ42 biomarker into the clinic
Henrik Schinke
• 15 Dec 2022
5:44
Targeting the pancreas to treat Alzheimer’s disease
Florin Despa
• 28 Nov 2022
2:11
Promise of microRNAs as Alzheimer’s disease markers
Bruno Steinkraus
• 1 Dec 2022
3:01
Diabetes-associated cognitive dysfunction
Florin Despa
• 28 Nov 2022
7:25
The importance of using systems biology based approaches in AD research
Jared Roach
• 22 Nov 2022
2:36
The regulatory role of nicotinic receptors in cognitive functioning
Paul Newhouse
• 23 Nov 2022
7:29
New pivotal study using photobiomodulation in Alzheimer’s treatment
Jacques Touchon
• 9 Dec 2022
10:42
Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI
Zahinoor Ismail
• 15 Dec 2022
1:36
How effective are cholinergic agents beyond MCI?
Paul Newhouse
• 23 Nov 2022
1
2
3
4
5
Next